Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Lowy

Showing results (381-390 of 401) with videos related to

Pageof 41
Sort By:
The Journal of Infectious Diseases|June 25, 2014
Reduced prevalence of vulvar HPV16/18 infection among women who received the HPV16/18 bivalent vaccine: a nested analysis within the Costa Rica Vaccine TrialKrystle A Lang Kuhs, Paula Gonzalez, Ana Cecilia Rodriguez, et al.
Journal of the National Cancer Institute|September 28, 2017
Durability of Protection Afforded by Fewer Doses of the HPV16/18 Vaccine: The CVT TrialMahboobeh Safaeian, Joshua N Sampson, Yuanji Pan, et al.
Journal of the National Cancer Institute|February 25, 2020
Durability of Cross-Protection by Different Schedules of the Bivalent HPV Vaccine: The CVT TrialSabrina H Tsang, Joshua N Sampson, John Schussler, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 17, 2011
Targeting the vaginal mucosa with human papillomavirus pseudovirion vaccines delivering simian immunodeficiency virus DNAShari N Gordon, Rhonda C Kines, Galyna Kutsyna, et al.
Microbiology Spectrum|January 12, 2022
A Trans-Governmental Collaboration to Independently Evaluate SARS-CoV-2 Serology AssaysLigia A Pinto, Ribhi M Shawar, Brendan O'Leary, et al.
American Journal of Epidemiology|August 21, 2014
Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimatesKrystle A Lang Kuhs, Carolina Porras, John T Schiller, et al.
The Journal of Infectious Diseases|September 10, 2013
Prevalence of and risk factors for oral human papillomavirus among young women in Costa RicaKrystle A Lang Kuhs, Paula Gonzalez, Linda Struijk, et al.
Journal of the National Cancer Institute|February 25, 2020
Evaluation of Durability of a Single Dose of the Bivalent HPV Vaccine: The CVT TrialAimée R Kreimer, Joshua N Sampson, Carolina Porras, et al.
Journal of the National Cancer Institute|May 31, 2022
Performance of Cervical Screening a Decade Following HPV Vaccination: The Costa Rica Vaccine TrialShang-Ying Hu, Aimée R Kreimer, Carolina Porras, et al.
The Lancet. Oncology|December 3, 2020
Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine TrialCarolina Porras, Sabrina H Tsang, Rolando Herrero, et al.
Pageof 41

Showing results (381-390 of 401) with videos related to

Sort By:
Pageof 41
The Journal of Infectious Diseases|June 25, 2014
Reduced prevalence of vulvar HPV16/18 infection among women who received the HPV16/18 bivalent vaccine: a nested analysis within the Costa Rica Vaccine TrialKrystle A Lang Kuhs, Paula Gonzalez, Ana Cecilia Rodriguez, et al.
Journal of the National Cancer Institute|September 28, 2017
Durability of Protection Afforded by Fewer Doses of the HPV16/18 Vaccine: The CVT TrialMahboobeh Safaeian, Joshua N Sampson, Yuanji Pan, et al.
Journal of the National Cancer Institute|February 25, 2020
Durability of Cross-Protection by Different Schedules of the Bivalent HPV Vaccine: The CVT TrialSabrina H Tsang, Joshua N Sampson, John Schussler, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 17, 2011
Targeting the vaginal mucosa with human papillomavirus pseudovirion vaccines delivering simian immunodeficiency virus DNAShari N Gordon, Rhonda C Kines, Galyna Kutsyna, et al.
Microbiology Spectrum|January 12, 2022
A Trans-Governmental Collaboration to Independently Evaluate SARS-CoV-2 Serology AssaysLigia A Pinto, Ribhi M Shawar, Brendan O'Leary, et al.
American Journal of Epidemiology|August 21, 2014
Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimatesKrystle A Lang Kuhs, Carolina Porras, John T Schiller, et al.
The Journal of Infectious Diseases|September 10, 2013
Prevalence of and risk factors for oral human papillomavirus among young women in Costa RicaKrystle A Lang Kuhs, Paula Gonzalez, Linda Struijk, et al.
Journal of the National Cancer Institute|February 25, 2020
Evaluation of Durability of a Single Dose of the Bivalent HPV Vaccine: The CVT TrialAimée R Kreimer, Joshua N Sampson, Carolina Porras, et al.
Journal of the National Cancer Institute|May 31, 2022
Performance of Cervical Screening a Decade Following HPV Vaccination: The Costa Rica Vaccine TrialShang-Ying Hu, Aimée R Kreimer, Carolina Porras, et al.
The Lancet. Oncology|December 3, 2020
Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine TrialCarolina Porras, Sabrina H Tsang, Rolando Herrero, et al.
Pageof 41